Compare MDV & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDV | SPRO |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | 9 | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.5M | 156.3M |
| IPO Year | N/A | 2017 |
| Metric | MDV | SPRO |
|---|---|---|
| Price | $17.88 | $2.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $18.00 | N/A |
| AVG Volume (30 Days) | 58.1K | ★ 1.4M |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | ★ 7.50% | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $66,802,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.56 | $300.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $13.80 | $1.80 |
| 52 Week High | $18.83 | $3.09 |
| Indicator | MDV | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 48.08 | 36.21 |
| Support Level | $17.60 | $2.19 |
| Resistance Level | $18.75 | $2.47 |
| Average True Range (ATR) | 0.39 | 0.26 |
| MACD | -0.14 | -0.07 |
| Stochastic Oscillator | 21.14 | 22.29 |
Modiv Industrial Inc is a pioneer in the direct-to-consumer commercial real estate product industry. It provides individual investors access to real estate and real estate-related investments designed to provide both income and long-term growth. The company has invested in single-tenant income-producing properties. Its current business consists of owning, managing, operating, leasing, acquiring, investing in, and disposing of commercial real estate assets utilized for industrial manufacturing, as well as a few non-core assets. All of the company's consolidated revenues are derived from the company's consolidated real estate properties.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.